Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protagonist Therapeutics (PTGX) Profit After Tax (2017 - 2025)

Protagonist Therapeutics' Profit After Tax history spans 9 years, with the latest figure at -$44.4 million for Q4 2025.

  • For Q4 2025, Profit After Tax fell 133.71% year-over-year to -$44.4 million; the TTM value through Dec 2025 reached -$130.1 million, down 147.29%, while the annual FY2025 figure was -$130.1 million, 147.29% down from the prior year.
  • Profit After Tax for Q4 2025 was -$44.4 million at Protagonist Therapeutics, down from -$39.3 million in the prior quarter.
  • Across five years, Profit After Tax topped out at $207.3 million in Q1 2024 and bottomed at -$44.4 million in Q4 2025.
  • The 5-year median for Profit After Tax is -$33.5 million (2023), against an average of -$9.3 million.
  • The largest annual shift saw Profit After Tax tumbled 335.45% in 2021 before it surged 714.8% in 2024.
  • A 5-year view of Profit After Tax shows it stood at -$36.9 million in 2021, then rose by 7.35% to -$34.2 million in 2022, then skyrocketed by 179.94% to $27.3 million in 2023, then surged by 381.7% to $131.7 million in 2024, then plummeted by 133.71% to -$44.4 million in 2025.
  • Per Business Quant, the three most recent readings for PTGX's Profit After Tax are -$44.4 million (Q4 2025), -$39.3 million (Q3 2025), and -$34.8 million (Q2 2025).